Edition:
United States

Thermo Fisher Scientific Inc (TMO.N)

TMO.N on New York Stock Exchange

189.39USD
12:44pm EST
Change (% chg)

$-2.08 (-1.09%)
Prev Close
$191.47
Open
$191.29
Day's High
$193.08
Day's Low
$189.15
Volume
83,451
Avg. Vol
430,312
52-wk High
$201.20
52-wk Low
$139.88

Summary

Name Age Since Current Position

Jim Manzi

65 2007 Independent Chairman of the Board

Marc Casper

49 2009 President, Chief Executive Officer, Director

Stephen Williamson

50 2015 Chief Financial Officer, Senior Vice President

Mark Stevenson

54 2017 Chief Operating Officer, Executive Vice President, President, Life Sciences Solutions

Seth Hoogasian

62 2006 Senior Vice President, General Counsel, Secretary

Patrick Durbin

50 2015 Senior Vice President, President - Specialty Diagnostics

Daniel Shine

48 2016 Senior Vice President, President, Analytical Instruments

Peter Hornstra

57 2007 Vice President, Chief Accounting Officer

Dion Weisler

49 2017 Director

Nelson Chai

51 2010 Independent Director

C. Martin Harris

60 2012 Independent Director

Tyler Jacks

56 2009 Independent Director

Judy Lewent

68 2008 Independent Director

Thomas Lynch

62 2009 Independent Director

William Parrett

72 2008 Independent Director

Lars Sorensen

63 2016 Independent Director

Scott Sperling

59 2006 Independent Director

Elaine Ullian

69 2001 Independent Director

Kenneth Apicerno

Vice President, Investor Relations

Biographies

Name Description

Jim Manzi

Mr. Jim P. Manzi is an Independent Chairman of the Board of the Company. He was also Chairman of the Board from January 2004 to November 2006. He has been the Chairman of Stonegate Capital, a firm he formed to manage private equity investment activities in technology startup ventures, primarily related to the Internet, since 1995. From 1984 until 1995, he served as the Chairman, President and Chief Executive Officer of Lotus Development Corporation, a software manufacturer that was acquired by IBM Corporation in 1995. We believe that Mr. Manzi is well suited to serve on our Board due to his senior management experience leading Lotus and overall business acumen.

Marc Casper

Mr. Marc N. Casper is President, Chief Executive Officer, Director of the Company. He joined the Company in November 2001 and has been its President and Chief Executive Officer since October 2009. He served as the Company’s Chief Operating Officer from May 2008 to October 2009 and was Executive Vice President from November 2006 to October 2009. Prior to being named Executive Vice President, he was Senior Vice President from December 2003 to November 2006. Prior to joining the Company, Mr. Casper served as president, chief executive officer and a director of Kendro Laboratory Products. Mr. Casper is also a director of U.S. Bancorp. Within the last five years, Mr. Casper was a director of Zimmer Holdings, Inc. We believe that Mr. Casper is well suited to serve on our Board due to his position as Chief Executive Officer of the Company as well as his 20 years in the life sciences/healthcare equipment industry.

Stephen Williamson

Mr. Stephen Williamson is Chief Financial Officer, Senior Vice President of the Company. He was Vice President of Financial Operations from May 2008 to August 2015.

Mark Stevenson

Mr. Mark P. Stevenson has been appointed as Chief Operating Officer, Executive Vice President, President, Life Sciences Solutions of the Company. Prior to the acquisition of Life Technologies Corporation (“Life Technologies”), Mr. Stevenson was President and Chief Operating Officer of Life Technologies from November 2008 to February 2014 and previously President and Chief Operating Officer of Applied Biosystems, Life Technologies’ predecessor entity, from December 2007 to November 2008.

Seth Hoogasian

Mr. Seth H. Hoogasian is Senior Vice President, General Counsel and Secretary of the Company. He was Vice President from 1996 to November 2006.

Patrick Durbin

Mr. Patrick M. Durbin is Senior Vice President, President-Specialty Diagnostics of the Company. He was President of the BioPharma Services business from January 2010 to October 2015.

Daniel Shine

Mr. Daniel P. Shine is Senior Vice President, President, Analytical Instruments of the Company. He was President of the Chromatography and Mass Spectrometry business from November 2012 to January 2016. He was President of the Chemical Analysis business from July 2011 to November 2012 and President of the Process Instruments business from April 2007 to July 2011.

Peter Hornstra

Mr. Peter E. Hornstra is Vice President, Chief Accounting Officer of the Company. He was Corporate Controller from January 1996 to February 2007.

Dion Weisler

Mr. Dion J. Weisler serves as Director of the Company. He has been President and Chief Executive Officer of HP Inc., a business that includes personal computers, mobility devices, technical workstations, printers, graphics solutions, managed-print services and internet services, since November 2015, following the separation of Hewlett-Packard Company ("Hewlett-Packard") into two independent companies. He joined Hewlett-Packard in January 2012 as Senior Vice President, Printing and Personal Systems and was appointed Executive Vice President, Printing and Personal Systems in June 2013. Mr. Weisler is also a director of HP Inc. We believe that Mr. Weisler is well suited to serve on our Board due to his senior management experience at a global company.

Nelson Chai

Mr. Nelson J. Chai is an Independent Director of the Company. He was appointed President and Chief Executive Officer of The Warranty Group, which delivers warranty solutions and related benefits to some of the world’s leading manufacturers, distributors, and retailers, as well as specialty insurance products and services for financial institutions. He previously was President of CIT Group Inc., a bank holding company, from August 2011 to December 2015. He joined CIT Group in June 2010 as Executive Vice President, Chief Administrative Officer and head of strategy. Prior to CIT Group, he was President, Asia-Pacific for Bank of America Corporation beginning in December 2008, and Executive Vice President and Chief Financial Officer of Merrill Lynch & Co., a financial services firm, from December 2007 to December 2008. We believe that Mr. Chai is well suited to serve on our Board due to his many years of experience in finance and accounting.

C. Martin Harris

Dr. C. Martin Harris, M.D., is an Independent Director of the Company. He was appointed Associate Vice President of the Health Enterprise and Chief Business Officer at the Dell Medical School at The University of Texas at Austin. Dr. Harris previously served since 2009 as the Chief Strategy Officer of The Cleveland Clinic Foundation, a multi-specialty academic medical center, and from June 1996 to December 2016, he had been the Chief Information Officer and Chairman of the Information Technology Division of and a Staff Physician for The Cleveland Clinic Hospital and The Cleveland Clinic Foundation Department of General Internal Medicine. Dr. Harris is also a director of Invacare Corporation, HealthStream Inc. and Colgate-Palmolive Company. We believe that Dr. Harris is well suited to serve on our Board due to his experience in the healthcare industry as a physician and leader of healthcare organizations and also his expertise in the use of information technology in the healthcare industry.

Tyler Jacks

Dr. Tyler Jacks, Ph.D. is an Independent Director of the Company. He is the David H. Koch Professor of Biology at the Massachusetts Institute of Technology (MIT) and director of the David H. Koch Institute for Integrative Cancer Research. He joined the MIT faculty in 1992 and was director of its Center for Cancer Research from 2001 to 2008. Since 2002, Dr. Jacks has been an investigator with the Howard Hughes Medical Institute. Dr. Jacks is also a director of Amgen Inc. We believe that Dr. Jacks is well suited to serve on our Board due to his experience as a cancer researcher and member of multiple scientific advisory boards in biotechnology companies, pharmaceutical companies and academic institutions.

Judy Lewent

Ms. Judy C. Lewent is an Independent Director of the Company. She was Chief Financial Officer of Merck & Co., Inc., a global pharmaceutical company, from 1990 until her retirement in 2007. She was also Executive Vice President of Merck from February 2001 through her retirement and had additional responsibilities as President, Human Health Asia from January 2003 until July 2005, when she assumed strategic planning responsibilities for Merck. Ms. Lewent is also a director of Motorola Solutions, Inc. and GlaxoSmithKline plc. We believe that Ms. Lewent is well suited to serve on our Board due to her many years of global experience in finance and the pharmaceutical industry.

Thomas Lynch

Mr. Thomas J. Lynch is an Independent Director of the Company. He is Executive Chairman of the Board of Directors of TE Connectivity Ltd. (formerly Tyco Electronics Ltd.), a global provider of engineered electronic components, network solutions, undersea telecommunication systems and specialty products. He previously was Chairman and Chief Executive Officer of TE Connectivity Ltd. He joined Tyco International in 2004 as President of Tyco Engineered Products and Services and was appointed Chief Executive Officer in January 2006, when Tyco Electronics was formed and later became an independent, separately traded entity and was appointed Chairman in January 2013. Mr. Lynch is also a director of Cummins Inc. We believe that Mr. Lynch is well suited to serve on our Board due to his experience as Chief Executive Officer of a comparably-sized global company.

William Parrett

Mr. William G. Parrett is an Independent Director of the Company. He served as Chief Executive Officer of Deloitte Touche Tohmatsu, a global accounting firm. Mr. Parrett joined Deloitte in 1967, and served in a series of roles of increasing responsibility. Mr. Parrett serves as a director of the Blackstone Group LP, Eastman Kodak Company and UBS AG, and is chairman of their Audit Committees. He also serves as a director of Conduent Inc. and, within the last five years, Mr. Parrett was a director of iGate Corporation. We believe that Mr. Parrett is well suited to serve on our Board due to his experience as Chief Executive Officer of Deloitte Touche Tohmatsu, which demonstrates his leadership capability and extensive knowledge of complex financial and operational issues.

Lars Sorensen

Mr. Lars Rebien Sorensen is an Independent Director of Thermo Fisher Scientific Inc. He was President and Chief Executive Officer of Novo Nordisk A/S, a global healthcare company with a leading position in diabetes care from November 2000 to January 2017. He held various senior management roles at Novo Nordisk after he joined the company in 1982. Mr. Sørensen also currently serves as a member of the supervisory board of Bertelsmann AG, a worldwide media company based in Germany, and Carlsberg A/S, an international brewing company. Within the last five years, he was a director of Dong Energy A/S and Danmarks Nationalbank. We believe that Mr. Sørensen is well suited to serve on our Board due to his experience as a Chief Executive Officer of a global healthcare company.

Scott Sperling

Mr. Scott M. Sperling is an Independent Director of the Company. Prior to the merger of Thermo Electron Corporation and Fisher Scientific International Inc., he was a director of Fisher Scientific from January 1998 to November 2006. He has been employed by Thomas H. Lee Partners, L.P., a leveraged buyout firm, and its predecessor, Thomas H. Lee Company, since 1994. Mr. Sperling currently serves as Co-President of Thomas H. Lee Partners, L.P. Mr. Sperling is also a director of iHeartMedia, Inc. and The Madison Square Garden Company. We believe that Mr. Sperling is well suited to serve on our Board due to his experience in acquisitions and finance.

Elaine Ullian

Ms. Elaine S. Ullian is an Independent Director of the Company. She was the President and Chief Executive Officer of Boston Medical Center, a 550-bed academic medical center affiliated with Boston University, from July 1996 to her retirement in January 2010. Ms. Ullian is also a director of Vertex Pharmaceuticals, Inc. and Hologic Inc. We believe that Ms. Ullian is well suited to serve on our Board due to her experience as Chief Executive Officer of Boston Medical Center, a healthcare provider similar to many of the Company’s customers.

Kenneth Apicerno

Basic Compensation